Price$8.69-0.15 (-1.70%)
01:30 PM05:15 PM
News · 26 weeks61+367%
2026-04-192026-10-11
Mix2690d
- Other11(42%)
- SEC Filings7(27%)
- Insider4(15%)
- Earnings2(8%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Verastem Inc.8-K - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 424B5 filed by Verastem Inc.424B5 - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 424B5 filed by Verastem Inc.424B5 - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 8-K filed by Verastem Inc.8-K - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its common stock at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross p
- PRVerastem Oncology Announces Planned Chief Executive Officer Transition and Succession PlanAccomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class investigational oral KRAS G12D (ON/OFF) inhibitor Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and member of Verastem’s Board of Directors Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective
- PRVS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of patients ongoing >6 months and a 67% landmark 6-month PFS rate FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end Early results in heavily pretreated 3L+ colorectal cancer (CRC) include 33% unconfirmed ORR with 900 mg QD in combination anti-EGFR therapy with no patients with target lesion increases VS-7375 achieved 43% confirmed ORR with 600 mg QD monotherapy in 2L+ non-small cell lung cancer (NSCLC) including patients with prior taxane tr
- PRVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $7.90, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on October 1, 2026. A tota
- INSIDERPresident and CEO Paterson Dan sold $352,968 worth of shares (44,121 units at $8.00) and gave a grant of 106,893 shares, decreasing direct ownership by 19% to 652,712 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERChief Financial Officer Calkins Daniel gave a grant of 8,333 shares and sold $20,528 worth of shares (2,566 units at $8.00), decreasing direct ownership by 8% to 123,781 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- PRVerastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerRAMP 201 study supported FDA Accelerated Approval of AVMAPKI FAKZYNJA CO-PACK for treatment of KRAS-mutated recurrent LGSOC following prior systemic therapy Across patients with KRAS wild-type and KRAS-mutated recurrent LGSOC, the combination had a median duration of response of 31.1 months, median progression free survival of 12.9 months, and a safety profile consistent with the primary analysis Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology (SGO), has published two-year long-term res
- PRKRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034SAN DIEGO, Sept. 28, 2026 /CNW/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question
- PRVerastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global MeetingOral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patients New external control arm analysis of avutometinib plus defactinib versus standard-of-care treatment for LGSOC will be presented during Poster Rounds Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that an abstract about molecular profiling and tumor biomarker analysis from the Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC) has been selected for a late-breaking o
- INSIDERChief Financial Officer Calkins Daniel sold $424 worth of shares (55 units at $7.70), decreasing direct ownership by 0.05% to 118,014 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- ANALYSTWolfe Research initiated coverage on VerastemWolfe Research initiated coverage of Verastem with a rating of Outperform
- PRVerastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal CancersInvestor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical update reported in June 2026 and provide the first broader safety and efficacy assessment of VS-7375 across these tumor types. VS-7375 is a potent
- PRVerastem Oncology to Participate in Upcoming September Investor ConferencesVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET A live webcast of the fireside chats can be accessed under "Events & Presentations" on the Company’s website at www.verastem.com. A replay of the webcasts will be
- SECSEC Form SCHEDULE 13G filed by Verastem Inc.SCHEDULE 13G - Verastem, Inc. (0001526119) (Subject)
- SECVerastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 10-Q filed by Verastem Inc.10-Q - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesAVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from Oberland fa
- INSIDERPresident and CEO Paterson Dan sold $7,565 worth of shares (1,302 units at $5.81), decreasing direct ownership by 0.22% to 589,940 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- PRVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal CancerTARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab and chemotherapy for frontline treatment of metastatic colorectal cancer KRAS G12D is one of the most common KRAS variants in metastatic colorectal cancer, occurring in approximately 15% of patients All three TARGET-D registration-directed Phase 2 clinical trials now enrolling following first-patient dosing across pancreatic, colorectal, and lung cancers Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new m
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- PRVerastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceut
VSTM FAQ
7 questionsWhat does Verastem Inc. do?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal...Where does VSTM stock trade?
Verastem Inc. (VSTM) is listed on NASDAQ.What sector and industry is VSTM in?
Verastem Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verastem Inc. go public?
Verastem Inc. (VSTM) completed its IPO in 2012.What are analysts saying about VSTM?
Verastem Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-09-17. Recent price targets range from $1000.00 to $2000.00.What companies are similar to VSTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VSTM side-by-side with any of them on Quantisnow.How can I track VSTM on Quantisnow?
Quantisnow aggregates Verastem Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VSTM to receive live email and push alerts on every new disclosure.